RETURN BIDS TO:
RETOURNER LES SOUMISSIONS À:

Bid Receiving - PWGSC / Réception des soumissions - TPSGC
11 Laurier St. / 11, rue Laurier
Place du Portage , Phase III
Core 0A1 / Noyau 0A1
Gatineau, Québec K1A 0S5
Bid Fax: (819) 997-9776

SOLICITATION AMENDMENT
MODIFICATION DE L'INVITATION

The referenced document is hereby revised; unless otherwise indicated, all other terms and conditions of the Solicitation remain the same.

Ce document est par la présente révisé; sauf indication contraire, les modalités de l'invitation demeurent les mêmes.

Comments - Commentaires

Title - Sujet QUANTUM DOT NANOTECHNOLOGY	
Solicitation No. - N° de l'invitation W7714-091142/A	**Amendment No. - N° modif.** 003
Client Reference No. - N° de référence du client W7714-091142	**Date** 2012-02-20
GETS Reference No. - N° de référence de SEAG PW-$$SV-057-23445	
File No. - N° de dossier 057sv.W7714-091142	**CCC No./N° CCC - FMS No./N° VME**
Solicitation Closes - L'invitation prend fin **at - à 02:00 PM** **on - le 2012-03-01**	**Time Zone** **Fuseau horaire** Eastern Standard Time EST
F.O.B. - F.A.B. **Plant-Usine:** ☐ **Destination:** ☐ **Other-Autre:** ☐	
Address Enquiries to: - Adresser toutes questions à: McRae, Scott	**Buyer Id - Id de l'acheteur** 057sv
Telephone No. - N° de téléphone (819) 956-1383 ( )	**FAX No. - N° de FAX** ( ) -
Destination - of Goods, Services, and Construction: **Destination - des biens, services et construction:**	

Vendor/Firm Name and Address
Raison sociale et adresse du fournisseur/de l'entrepreneur

Instructions: See Herein

Instructions: Voir aux présentes

Delivery Required - Livraison exigée	**Delivery Offered - Livraison proposée**

Vendor/Firm Name and Address
Raison sociale et adresse du fournisseur/de l'entrepreneur

Telephone No. - N° de téléphone
Facsimile No. - N° de télécopieur

Name and title of person authorized to sign on behalf of Vendor/Firm (type or print)
Nom et titre de la personne autorisée à signer au nom du fournisseur/ de l'entrepreneur (taper ou écrire en caractères d'imprimerie)

Signature **Date**

Issuing Office - Bureau de distribution

Science Procurement Directorate/Direction de l'acquisition de travaux scientifiques
11C1, Phase III
Place du Portage
11 Laurier St. / 11, rue Laurier
Gatineau, Québec K1A 0S5

Canada

This Solicitation Amendment No. 003 is raised to answer questions from industry.

Part 1
Questions and Answers

#	Questions	Answers
9	We have a solution which can meet the technical requirements outlined in the RFP; however, this solution is currently not based on quantum dot technology. We have the ability to develop a product that meets the requirements of this RFP, including incorporating quantum dots. Yet, as part of the bid process we will not be able to demonstrate a current product which incorporates quantum dots as required in the mandatory demonstration clause (Attachment 3, Section 3). Can this requirement be made less stringent to allow us to demonstrate a non-quantum dot technology?	No, the requirement cannot be made less stringent. The mandatory and point-rated criteria are meant to evaluate only the Quantum Dot technology which is the mandate of this project. Therefore, opening the bidding process to other technologies is not feasible.
10	At the time of bid submission, must the Bidder have a binding contract with its subcontractor to specifically develop the technology solution described in the RFP or is a MOU (memorandum of understanding) between the bidder and subcontractor that they will co-develop the technology solution be sufficient?	We would request that in the Bidder's proposal there is reference to the specific subcontractor with whom the Bidder has negotiated an agreement that would be contingent on contract award. Tangible (written) proof of the existence of this agreement and the terms thereof would need to be provided precedent to contract award.
11	Related to question #10, since a formal agreement does not exist between Bidder and subcontractor, the Bidder cannot identify or certify "every individual proposed in its bid will be available to perform the Work as required ..." (Attachment 4, Section 3). Can this mandatory requirement be relaxed?	The Bidder, to the best of his/her knowledge, should be able to certify that all personnel named in the proposal will be available for the work of the contract. Or if, for unforeseeable reason(s), certain personnel are not available at time of contract award, the Bidder would certify that every attempt will be made to replace that person(s) with person(s) with equivalent knowledge/expertise/experience. This certification would form part of the written agreement with the subcontractor, which would form part of the bid proposal, and would need to be provided precedent to contract award.

12	With respect to IP provisions (Attachment 4, Section 5), we have a clear understanding of the IP landscape to protect and commercialize our technology. This strategy involves in-licensing certain IP which we have identified and have had preliminary discussions with the IP owners. However, we do not intend on formalizing a final contract with IP owners until later this year. At time of bid submission, must Bidders provide evidence that they possess all required IP to commercialize their technology or can Bidders formalize any required IP licensing requirements subsequent to their bids being submitted?	The ownership of all background IP needs to be identified and written proof, forming part of the bid package, needs to be provided stating that the licensed owner is willing to license the IP to the bidder, precedent to contract award. The terms of the licensing agreement could be negotiated in good faith within a certain time limit. Please note that IP is addressed in the point-rated criteria.
13	**Refer to Annex A - SOW, Section 5.3.2(IV):** Is it possible to have more than one test per sample such that one test would be devoted to multiplex detection of one pathogen. For example, could more than one dipstick be possible for a sample in which each dipstick identifies one pathogen?	No, there should not be more than one dipstick for a sample in which each dipstick identifies one pathogen. The quantum dot technology must allow for the interrogation of a single sample for more than one pathogen or the identification of more than one pathogen if present in a single sample i.e., multiplex capability.

ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED